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Abstract: Despite improvement in infection control measures and surgical practice, surgical 
site infections (SSIs) remain a major cause of morbidity and mortality. In colorectal surgery, 
perioperative administration of a suitable antimicrobial regimen that covers both anaerobic 
and aerobic bacteria is universally accepted. In a prospective, double-blind, randomized study 
ertapenem was recently found to be more effective than cefotetan, a parenteral cephalosporin so 
broadly used as to be considered as gold standard in the prevention of SSIs following colorectal 
surgery. In this adequate and well controlled study, the superiority of ertapenem over cefotetan 
was clearly demonstrated from the clinical and bacteriological points of view. However, data 
that directly compares ertapenem with other antimicrobial regimen effective in preventing 
SSIs following colorectal surgery are lacking; furthermore, the possible risk of promotion of 
carbapenem resistance associated with widespread use of ertapenem prophylaxis as well as 
the ertapenem effects on the intestinal gut flora are of concern. Further comparative studies of 
ertapenem versus other widely used prophylactic regimens for colorectal surgery in patients 
submitted to mechanical bowel preparation versus no preparation as well as further research 
on adverse events of antibiotic prophylaxis, including emergence of resistance and Clostridium 
difficile infection, seem warranted.
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Introduction
Surgical site infections (SSIs) are defined as infections occurring within 30 days – or 
within one year in the case of implantation of a foreign body – after a surgical 
operation, and affecting either the incision, superficially or deeply, or organs, or body 
spaces at the site of operation.1 Despite improvement in infection control measures 
and surgical practice, SSIs remain a major cause of morbidity and mortality and result 
in additional expenses to cover excessive hospitalization, treatment, and additional 
surgical procedures. The length of stay for patients who have a postoperative infection 
is 3–11 days and 9.8 days longer in studies from the US and Europe, respectively,2–7 
than hospitalization for patients not undergoing postoperative complications. In the 
1990s, the mean direct costs due to a postoperative infection have been estimated 
to be US$3,000,8 adding 10%–20% to the cost of the total hospital bill.9 In a recent 
study of hospital costs attributable to surgical complications an increased cost of 
US$1,309 per patient and infection was found.2 As for colorectal surgery, costs of 
US$42,516 ± 39,972 and of US$10,999 ± 7,122 for each infected versus uncomplicated 
operation, have recently been described.10 On average, US$6,200/patient of home health 
expenses related to a wound care has also been found for wound infections following Therapeutics and Clinical Risk Management 2009:5 830
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colorectal operations which are diagnosed and treated at 
home.11 Overall, it has been estimated that SSIs contribute 
to 3.7 million excess hospital days, and over US$1.6 billion 
in hospital and patient costs.12,13 In Europe, available data 
suggest that the mean cost of prolonged hospitalization due 
to a postoperative infection is €325 per day.7 Deep SSIs 
involving organs or body spaces are associated with an even 
longer length of stay and increases in costs than superficial 
postoperative infections affecting only the incision.14
Incidence of SSIs
The incidence of SSIs varies widely between surgical 
procedures, hospitals and surgeons, and between patients.15 
According to data from the Centers for Disease Control – 
National Nosocomial Infections Surveillance (CDC-NNIS) 
system, SSIs account for 14%–16% of reported nosoco-
mial infections among all hospitalized patients, and 38% 
among surgical patients.1,16 In Europe, available data show 
that the incidence of these infections can be as high as 
20%, depending on the surgical procedure considered, the 
surveillance criteria used, and the study design.17 Due to 
high risk of bacterial contamination from the flora of the 
patient’s large bowel during operation, colorectal surgery 
is associated with a particularly high risk of postoperative 
infection. SSI rates of up to 40% and of about 25% have been 
found in patients not receiving18 or receiving11 perioperative 
antibiotic prophylaxis, respectively. Indeed, the opening 
of the intestinal lumen always involves a relevant risk for 
bacterial contamination of the operative field and therefore 
for postoperative wound infection. In patients having surgical 
wound infection following operations on the large intestine, 
the risk of death is doubled, intensive care unit admission 
more likely, and the average hospital stay is increased by 
five days.8 Furthermore, the risk of hospital readmission is 
greatly increased.8
Pathophysiology and microbiology 
of SSIs in colorectal surgery
Although pathogens responsible for SSIs may originate 
from exogenous sources, either intraoperatively, such as 
from members of the surgical team, the surgical theater 
environment, and equipment, or postoperatively, such as 
from drains or surgical wound dressings, most surgical 
infections are acquired intraoperatively, and the responsible 
pathogens originate from the patient’s endogenous flora.1 
In large bowel surgery, which is the site associated with the 
greatest incidence of postoperative infections, the opening 
of the viscera can cause dissemination into the operative 
field of fecal microorganisms located into the colon and 
rectum. If the surgical procedures are carried out with skilled 
technique, and in the absence of pre-existing local infection, 
the colorectal operation with opening of colorectum is 
considered a clean–contaminated operation.19 On the 
contrary, if during operation a considerable fecal spillage 
occurs due to a break in surgical technique, colorectal surgery 
is considered a contaminated operation.
After microbial contamination of the operative field, the 
risk of a SSI depends on the dose and virulence of contami-
nating microorganisms and the level of resistance of patient. 
The relationship is the following:
Risk of SSI
Dose of bacterial contamination virulence
Resis
=
×
t tance of patient
Clinically apparent infection results when bacterial 
contamination overcomes host defense mechanisms. The 
risk of postoperative infection is considered to be elevated 
when the level of contamination exceeds 105 microorgan-
isms per gram of tissue,20 although lower doses may be 
sufficient if foreign materials, such as suture, are present in 
the operative field.1,21 The virulence of the infecting micro-
organism depends on its ability to produce toxins and/or 
other factors which can increase the bacterial invasion and 
damage of tissues. Violation in sterile technique, preopera-
tive shaving, prolonged preoperative hospitalization, and 
presence of a remote infection, have also been linked to an 
increased risk of postoperative infection.1,21,22 Other risk 
factors for postoperative infection related to the surgical 
procedure include quality of surgical care, type and dura-
tion of surgery, emergency procedure, blood transfusion, 
intraoperative hypothermia, and systemic hypoxemia.23–26 
As for patient resistance, intrinsic patient characteristics 
strictly correlating with an increased risk of wound infec-
tion include advanced age (at least up to 65 years),27 an 
American Society of Anesthesiologists (ASA) score of 
III,21,28 obesity,11,29 pre-existing illness,22 and host defense 
deficiency.
SSIs following colorectal surgery are usually polymicrobial 
infections because of the very rich bacterial flora of the 
colorectal tract (106–108 and 109–1011 microorganisms per 
g/fecium for aerobes and anaerobes, respectively).30 Indeed, 
in the septic complications following surgical opening 
of distal intestinal tract, the most common finding is a 
mixed enteric flora of aerobes and anaerobes, with culture 
of up to 4–5 different species of aerobic and anaerobic 
microorganisms. The predominant isolates are Bacteroides 
fragilis and Escherichia coli; however other Gram-negative Therapeutics and Clinical Risk Management 2009:5 831
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rods, Enterococcus spp, as well as other anaerobes including 
other members of the Bacteroides group, Fusobacterium 
spp, Peptococcus spp, and Peptostreptococcus spp can also 
be isolated.30 Over the last 15 years, a rise in both Gram-
positive and Gram-negative resistant organisms in noso-
comial infections has been described. In surgical patients, 
Gram-positive bacteria, and mainly methicillin-resistant 
staphylococci, are causing more and more serious infec-
tions than ever before. Indeed, the impact of these infections 
can be profound, ranging from prolonged hospital stay and 
increased morbidity and mortality.31,32 However, SSIs caused 
by methicillin-resistant staphylococci are mainly observed 
following clean surgery, and especially clean prosthetic 
operations, such as orthopedic or cardiothoracic surgical 
procedures, and are rarely found in deep and organ space 
infections following colorectal surgery.33
Antimicrobial prophylaxis 
in colorectal surgery
It is universally accepted that antibiotic prophylaxis, 
ie, perioperative administration of suitable antimicrobial 
agents, must be considered one of the most important 
measures in order to prevent SSI in colorectal surgery. 
In 1981, Baum and colleagues compared the incidence of 
wound infection and mortality rates of patients given anti-
microbial prophylaxis for colorectal surgery with those of 
controls not given antimicrobial agents. By pooling data from 
26 trials published from 1965 to 1980, they found that the 
wound infection rate was significantly higher in the control 
group, with 36% of patients developing SSI compared with 
22% in the prophylactic antibiotic given group.18 Therefore, 
these authors recommended that no further trials of antimi-
crobial prophylaxis versus placebo be performed in colorectal 
surgery. However, despite the recommendation of Baum and 
colleagues, at least an additional four placebo-controlled 
studies have been published since 1981.34–37 All found that 
SSI rates were significantly lower in the antibiotic-treated 
groups (12.9% versus 40.2% on pooled data from the four 
studies; pooled odds ratio = 0.24; 95% confidence interval 
[CI]: 0.13, 0.43).
Antimicrobial prophylaxis in colorectal operations can 
be done by administering antimicrobial agents either orally 
or systemically. The mechanisms of prophylaxis for oral and 
systemic regimens are quite different. The most important 
effect of the oral regimens is to reduce quantitatively the 
microbial flora of the digestive tract before operation. 
Parenteral systemic antibiotics, on the contrary, although 
certainly able to change the colonic microflora,38 have less 
impact on the quantity of aerobic and anaerobic bacteria 
within the large bowel at the time of operation, especially if 
single-dose prophylaxis is administered. Indeed, the proven 
efficacy of perioperative systemic antimicrobial agents 
is mainly related to the suppression of bacterial growth 
in the tissues of the operative field once contamination 
occurred. However, the aim of systemic prophylaxis is not 
the sterilization of the tissues in case of contamination, but 
rather to facilitate the function of the patient immune defense 
mechanisms by suppressing, or at least decreasing, bacterial 
growth in the surgical site. The two different mechanisms can 
also be combined by giving antimicrobial agents both orally 
and intravenously. Worldwide, there is a general consensus on 
the administration of prophylactic antibiotics intravenously; 
however, especially in North America, many colorectal 
surgeons – up to 88% by 1990,39 86.5% by 1997,40 and up to 
75% by 200341 – prefer to administer a combined prophylaxis, 
ie, to give both oral and parenteral antibiotics.
As for the choice of antimicrobial agents for prophylaxis 
in colorectal surgery, there is a general agreement that 
antibiotic choices that cover both anaerobic and aerobic 
bacteria give the best results. Indeed, published trials show 
that the addition of an antibiotic covering aerobic intestinal 
flora in patients receiving an antimicrobial agents that cover 
anaerobic bacteria significantly reduced the incidence of 
SSIs.42 In the same way, the addition of an anaerobic coverage 
to aerobic coverage also resulted in a statistically significant 
reduction in SSI rate.42
In 1998, Song and Glenny43 published a systematic review 
of 147 randomized trials in colorectal surgery in which more 
than 70 different antibiotic regimens were tested. The main 
conclusions of the authors were that antimicrobial prophy-
laxis is effective for the prevention of SSIs in colorectal 
surgery and that there are no significant differences in the 
prophylactic efficacy among the different antimicrobials 
studied. Furthermore, they found that a single-dose or short-
term regimen is as efficacious as long-term, postoperative 
administration of antimicrobial agents and that no signifi-
cant difference in the rate of SSI can be found between a 
single-dose regimen and a multidose regimen. Finally, no 
additional benefit could be observed in six trials in which 
parenteral alone were compared with parenteral plus oral 
prophylactic antibiotics. However, combined prophylaxis 
in colorectal surgery has been studied in several other 
trials published after the 1998. Results of these studies are 
conflicting. In a double-blind, placebo-controlled, random-
ized study on 215 patients undergoing elective colorectal 
surgery published by Lewis in 2002, combined oral and Therapeutics and Clinical Risk Management 2009:5 832
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systemic antibiotics (neomycin and metronidazole orally + 
amikacin and metronidazole intravenously) were found to 
be superior to systemic antibiotics alone (amikacin and 
metronidazole) in preventing SSIs.44 These conclusions 
were also supported by a meta-analysis on combined 
oral and systemic antibiotics versus systemic antibiotic 
alone performed by Lewis on his own study plus 12 other 
randomized clinical studies published from 1975 to 1995.44 
On the contrary, no difference in SSI rate was found by 
Espin-Basany and colleagues in a study of 300 patients 
undergoing elective colorectal resection who received three 
doses of cefoxitin intravenously and who were randomized 
to receive either three doses of oral antibiotics (neomycin 
and metronidazole) or one dose of oral antibiotics or no oral 
antibiotics.45 Recently, Kobayashi and colleagues found no 
advantage in the prevention of SSI by adding oral antibiot-
ics to intravenous antimicrobial prophylaxis in colorectal 
surgery on 491 patients.46 Nelson and colleagues recently 
published a systematic review on antibiotic prophylaxis in 
colorectal surgery including 182 randomized controlled trials 
with more than 30,800 patients and 50 different antibiotics 
focused on a single outcome, which was the infection of 
the abdominal surgical wound.42 Meta-analyses performed 
in this study confirmed no statistically significant differ-
ences when comparing short- or long-term duration of 
prophylaxis or single dose versus multiple dose antibiotics. 
It was also found that antibiotic regimens should include 
cover against both aerobic and anaerobic bacteria. Finally, 
a statistically significant benefit in favor of combined oral 
and intravenous dosing when compared to intravenous 
alone (relative risk [RR] 0.55, 95% CI: 0.41–0.74) or 
oral alone (RR 0.34, 95% CI: 0.13–0.87) was shown in 
thirteen reports including 2,362 patients and three studies 
(283 patients), respectively.
However, it should be noted that the use of oral antibiotics 
increase the incidences of gastrointestinal adverse effects 
including nausea, vomiting, abdominal pain, diarrhea, 
and Clostridium difficile colonization and infection.45,47–49 
In a study of 300 patients who received three doses of 
intravenous cefoxitin and who were randomized to receive 
either three doses (Group A), one dose (Group B), or no 
oral antibiotics (neomycin and metronidazole) (Group C), 
vomiting occurred in 31%, 11%, and 9% of the patients 
(Groups A, B, and C, respectively, P  0.001); nausea was 
present in 44%, 18%, and 13% of patients (P  0.001), 
and abdominal pain was recorded in 13%, 10%, and 4% of 
patients (P  0.077).45 In another randomized comparative 
study of 137 patients receiving oral, systemic, or combined 
prophylaxis, no significant differences in the incidence of 
SSI among the three groups were found, but the oral anti-
biotic regimen induced a greater change in the intestinal 
flora and was associated with more frequent postoperative 
diarrhea.48 In another trial49 the rate of C. difficile infection 
was higher in patients who received combined prophylaxis 
(7.4%) compared with patients who received only paren-
teral antibiotics (2.6%; P = 0.03). However, all the patients 
enrolled in these studies received also mechanical bowel 
preparation (MBP), and it is well known that mechanical 
cleansing takes part in altering the normal enteric flora, 
increasing the risk of intestinal adverse events and C. difficile 
infection. The matter is even more complicated because 
mechanical bowel preparation has universally been adopted 
for patients undergoing colorectal surgery and is not based 
on well designed prospective randomized studies, but 
based only on observational data and expert opinions,50 
and its role in lowering the rate of postoperative SSIs 
has been questioned by several recent studies.50–52 In two 
recent reviews, which included 13 and 14 controlled trials 
with 4,777 and 4,859 patients, respectively, Guenaga and 
colleagues53 and Slim and colleagues54 did not find any 
differences in SSIs and anastomotic leakage between the 
groups of patients who received MBP or had no preparation. 
If the practice of MBP is abandoned, the entire matter of 
oral prophylaxis in colorectal surgery including number of 
doses and administration timing needs to be re-evaluated. 
Furthermore, it is not known whether oral antibiotics would 
be still effective when the colon is not empty.
In conclusion, the use of antibiotic prophylaxis for 
patients undergoing colorectal surgery is imperative and 
some principles appear to be firmly stated: antibiotics should 
include coverage of both aerobic and anaerobic bacteria. For 
intravenous antibiotics, they must be administered only once 
before surgery. Several different antibiotics have been studied 
as parenteral prophylactic regimens in colorectal surgery with 
similar estimates of efficacy. It is therefore very difficult, 
if not impossible, to identify the best one.43 However, some 
parenteral antibiotic regimens, such as intravenous cefoxitin 
or cefotetan, are so broadly used as to be considered as gold 
standard, and to which other antibiotic choices should be 
compared.42,55–60
In the light of the more recent data against MBP, further 
studies seem instead necessary in order to firmly ascertain 
the role and the time of administration of oral antibiotics, 
whether administered alone or as combined prophylactic 
regimens, as oral antibiotics have not been studied in the 
uncleansed colon. Further research on adverse events of Therapeutics and Clinical Risk Management 2009:5 833
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antibiotic prophylaxis, especially C. difficile colonization and 
infection, in patients submitted to MBP versus no preparation, 
is also warranted.
Major properties of ertapenem
In vitro activity
Three multicenter studies on more than 10,000 recent clinical 
isolates, examining broad ranges of bacterial species from 
US, Europe, and Australia61–63 have so far been published on 
the in vitro activity of ertapenem, a parenteral broad-spectrum 
1-beta-methyl-carbapenem. According to the British Society 
for Antimicrobial Chemotherapy, breakpoints of susceptibility 
and resistance are 2 mg/L and 2 mg/L, respectively, for 
all species except pneumococci, where ertapenem has values 
of 1 mg/L and 1 mg/l, respectively.64
With rare exceptions, the minimum inhibitory con-
centrations (MICs) for Enterobacteriaceae fall between 
0.008 mg/L and 0.12 mg/L. On the contrary, ertapenem has 
only very limited activity against Pseudomonas aeruginosa 
isolates (with MICs ranging from 2 mg/L to 16 mg/L), and 
Acinetobacter spp (MICs generally exceeding 4 mg/L), 
and lacks activity against Stenotrophomonas maltophilia. 
As for Gram-positive microorganisms, ertapenem is active 
against both methicillin-susceptible Staphylococcus aureus 
and methicillin-susceptible coagulase negative staphylococci 
(with MICs ranging from 0.12 mg/L to 0.5 mg/L), Propi-
onibacterium acnes and most Corynebacterium spp, but 
has no activity against Enterococcus faecalis, Enterococcus 
faecium, and methicillin-resistant staphylococci. The activity 
against pneumococci is good, although sensitivity, as with all 
b-lactams, is reduced for penicillin nonsusceptible isolates. 
The activity against anaerobes is excellent: MICs of 1–2 mg/L 
have been found for Bacteroides fragilis group isolates, and 
virtually all Prevotella, Fusobacterium, Peptostreptococcus, 
and Porphyromonas spp. are susceptible at 0.5 mg/L. Most 
clostridia, including Clostridium difficile, are susceptible 
at 1–2 mg/L.
Pharmacokinetics and pharmacodynamics
The plasma half-life of ertapenem in healthy volunteers is 
approximately four hours, allowing once-daily administration.65 
This long half-life reflects binding to plasma proteins. Indeed, 
84%–96% of ertapenem is bound to plasma protein and 
this protein binding decreases as plasma concentrations of 
ertapenem increase.65 Only the unbound fraction of the drug 
can penetrate into the tissues; therefore only 4%–16% of the 
mean plasma concentration is responsible for the antmicrobial 
activity of ertapenem. Plasma concentrations of total drug 
with a daily dose of 1 g exceed the MIC90 for susceptible 
bacteria through most of the dosing interval, and free drug 
concentrations remains above the MIC90 for approximately 
six hours.66
About 80% of excretion is via the kidneys, with half as 
native compound. A further 10% is eliminated via the feces. 
If the creatinine clearance is 30 ml/min/1.73 m3, halving 
of the dose is suggested in the US, whereas in Europe it is 
suggested that ertapenem should not be administered at all. 
On the other hand, no adjustment is required for hepatic 
insufficiency, because ertapenem does not undergo either 
hepatic metabolism or significant biliary excretion.
Intra-abdominal tissue penetration of 1 g ertapenem 
has been studied in 48 patients requiring abdominal surgery.67 
The mean tissue concentration in the gall bladder (16.0 ± 
8.8 mg/kg),  colon  (12.1 ± 5.3 mg/kg),  small  bowel 
(7.0 ± 5.7 mg/kg), liver (4.5 ± 2.3 mg/kg), and pancreas 
(3.4 ± 2.9 mg/kg) were above MICs for susceptible bacte-
ria usually found in intra-abdominal infections, including 
E. coli, Enterobacteriaceae, and B. fragilis. Furthermore, 
the mean tissue/plasma ratio was 0.19 for the colon, 0.17 
for the small bowel and gall bladder, 0.088 for the liver and 
0.095 for the pancreas. Ertapenem’s concentrations in intra-
abdominal tissues at 25% of dosing interval (ie, six hours 
after administration) were at least 1.5 times above the MICs 
for susceptible bacteria usually found in intra-abdominal 
infections, and three times for B. fragilis, and 10 times 
for E. coli.
Therapeutic use
Ertapenem is licensed in Europe for the treatment of 
intra-abdominal and gynecological infections, community-
acquired pneumonia, and diabetic foot infections (without 
osteomyelitis). In the US and other countries it is also 
registered for skin and skin structure infections and for 
complicated urinary tract infections. Actually, major clinical 
trials in the above indications showed equivalence of ertap-
enem to comparators, ie, cefriaxone + metronidazole68 and 
piperacillin/tazobactam69 in the treatment of intra-abdominal 
and acute pelvic infections,70 ceftriaxone in community-
acquired pneumonia,71 piperacillin/tazobactam in skin 
and skin structure infections,72 and ceftriaxone in compli-
cated urinary tract infections.73,74 No serious side effects 
occurred in these trials. However, the intestinal adverse 
events observed are noteworthy: overall, diarrhea occurred 
in 1.7%–7% of ertapenem patients, and two out of 203 and 
two out of 274 patients treated with ertapenem displayed 
either C, difficile-associated diarrhea or pseudomembranous Therapeutics and Clinical Risk Management 2009:5 834
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colitis in trials on intra-abdominal infections70 and skin and 
soft tissue infections,73 respectively.
On the basis of its spectrum of activity, encompassing 
both aerobes and anaerobes, ertapenem must be considered 
to be mainly indicated in the treatment of complex mixed 
infections, and particularly of intra-abdominal infections 
acquired in the community, where Acinetobacter spp and 
P . aeruginosa are uncommon pathogens. However, owing 
to the long half-life, ertapenem could also be suitable as a 
single-dose prophylaxis in those surgical procedures, such 
as colorectal surgery, where prophylaxis must cover both 
anaerobic and aerobic bacteria.
Antibiotic prophylaxis 
with ertapenem in colorectal surgery
Aiming to find a possible parenteral antibiotic alternative 
to cefoxitin and cefotetan, whose manufacturers seem to be 
planning to discontinue the production,75 Itani and colleagues 
assessed the efficacy and safety of antibiotic prophylaxis with 
ertapenem as compared with cefotetan in patients undergoing 
elective colorectal surgery.75 Ertapenem was chosen in the 
light of its appropriate coverage against potential pathogens, 
attractive pharmacokinetic and pharmacodynamic character-
istics, and results of previous clinical studies.
In this prospective, double-blind, randomized, industry 
sponsored study, conducted between May 2002 and March 
2005 at 51 centers in the United States, patients aged 
18 years or older who were scheduled to undergo elective 
open surgery of the colon or rectum, and had sufficient 
time for MBP (sodium phosphate or polyethylene glycol), 
were randomly assigned in a 1:1 ratio to the study groups. 
They were given either a single dose of 1 g ertapenem or 
2 g cefotetan, which were infused over a 30-minute period 
within 60 minutes before the initial surgical incision was 
made. Patients were stratified according to whether the 
surgery was to include a resection of any portion of the 
rectum. The primary efficacy endpoint was the proportion of 
patients who could be evaluated and for whom prophylaxis 
was successful at the four-week follow-up assessment after 
surgery. Success was defined as no signs or symptom of 
infection at the surgical site, no anastomotic leakage, and 
no further need for surgery or antibiotic use for any reason. 
Treatment was considered to have failed, in addition to 
the above mentioned criteria, if a patient was treated with 
antibiotics for a distant site infection – even in the absence 
of signs or symptoms of surgical site infection – or missed 
the four-week assessment. To qualify for inclusion in the 
modified intention to treat analysis, patients were required 
to have undergone elective open colorectal surgery with 
standard MBP and to have received a dose of a study drug. 
In the per-protocol analysis were included patients who, in 
addition to the above criteria, have received a study drug 
within two hours before surgical incision and six hours 
before surgical closure, and have undergone the four-
week follow-up assessment. All the adverse events were 
collected until 14 days after the administration of antibiotic 
prophylaxis.
Of the 1,002 patients enrolled, 901 (451 in the ertapenem 
group and 450 in the cefotetan group) were included in the 
intention-to-treat analysis, and 672 (338 in the ertapenem 
group and 334 in the cefotetan group) were included in 
the per-protocol analysis. After adjustment for strata, in 
the modified intention to treat analysis the rate of overall 
prophylactic failure was 40.2% in the ertapenem group and 
50.9% in the cefotetan group (absolute difference, -10.7%, 
95% CI: -17.1 to -4.2). In the per-protocol analysis, the 
failure rate was 28.0% in the ertapenem group and 42.8% 
in the cefotetan group (absolute difference, -14.8%; 95% 
CI: -21.0 to -7.5). In the group of patients who underwent 
surgical procedures which did not include resection of rectum 
(253 patients receiving ertapenem and 265 patients receiving 
cefotetan) clinical failure occurred in 26.9% of patients 
treated with ertapenem and 43.4% of patients in the cefotetan 
group (absolute difference, -16.5%, 95% CI: -24.5 to -8.3). 
In the patients who underwent surgical procedures including 
resection of rectum (85 and 69 patients receiving ertapenem 
and cefotetan, respectively) clinical failure occurred in 
31.8% of patients in the ertapenem group and 40.6% of 
those receiving cefotetan (absolute difference, -8.8%; 95% 
CI: -23.9 to – 6.4). Both the intention-to-treat analysis and 
the per-protocol analysis fulfilled statistical criteria for the 
superiority of ertapenem. In the modified intention-to-treat 
analysis, the most common reason for failure of prophylaxis 
at the four-week assessment after surgery in both groups 
of patients was surgical site infection, which was 17.1% in 
the ertapenem group (12.3% superficial incisional infection, 
3.3% deep incisional infection, 1.5% organ-space infection), 
and 26.2% in patients receiving cefotetan (17.9% superficial 
incision infection, 5.1% deep incisional infection, 3.2% 
organ-space infection) (absolute difference, -9,1; 95% 
CI: -14,4 to -3.7).
None of the safety end points differed significantly 
between the two study groups. However, the overall incidence 
of diarrhea was 5.7% (27 out of 476) in the ertapenem group 
and 3.2% (15 out of 476) in the cefotetan group (P = 0.08). 
Furthermore, C. difficile infection occurred in eight of Therapeutics and Clinical Risk Management 2009:5 835
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476 patients in the ertapenem group (1.7%) and in three 
of 476 patients (0.6%) in the cefotetan group (P = 0.22).
An analysis of the microorganisms isolated in the 
failures of prophylaxis, with a correlation with the clinical 
outcomes reported by Itani and colleagues, was recently 
performed by Goldstein and colleagues.76 The in vitro activity 
of ertapenem was found to be superior to that of cefotetan 
against all anaerobic and many aerobic bacteria isolated from 
postoperative cultures of patients who failed prophylaxis. 
Indeed, of the 216 aerobes tested, 62.6% were resistant to 
cefotetan and 44% to ertapenem, and approximately half of 
the 158 anaerobes (50.7%) were resistant to cefotetan, being 
resistant to ertapenem only one anaerobe (Desulfobrivio 
fairfieldensis), isolated from a superficial incision infection. 
Furthermore, no ertapenem-resistant enteric microorganisms 
were isolated.
The potential cost impact of using ertapenem 1 g versus 
cefotetan 2 g as prophylaxis for elective open colorectal 
surgery was assessed in another post-hoc study by Wilson 
and colleagues in the patients included in the per-protocol 
analysis of the study by Itani and colleagues (338 in the 
ertapenem group and 334 in the cefotetan group).77 The 
mean ± standard deviation length of stay for all patients, 
including both prophylactic successes and failures, was 
7.6 ± 6.6 days for ertapenem and 8.7 ± 9.5 days for cefotetan. 
The overall mean per-patient cost of prophylactic drug 
and hospitalization room and board was US$15,245 with 
ertapenem and US$17,428 with cefotetan. A net saving of 
US$2,183 per patient with ertapenem relative to cefotetan 
prophylaxis was therefore found in prophylactic antibiotic 
drug and hospital costs.
Discussion
The original purpose of the study by Itani and colleagues 
was to demonstrate the noninferiority of ertapenem as 
compared with one conventional antibiotic (cefotetan), as a 
parenteral prophylactic agent in colorectal surgery. However, 
at the four-week assessment after surgery, ertapenem was 
found to be superior in terms of the overall proportion of 
favorable clinical responses and the incidence of postopera-
tive SSIs. Furthermore, ertapenem prophylaxis resulted in 
a shorter average length of stay, with a saving of more than 
US$2,000 per patient relative to cefotetan. It is surprising that, 
in the per-protocol analysis, the overall rates of prophylactic 
failures and of surgical-site infection in the cefotetan group 
were approximately 43% and 31%, respectively. These rates 
are much higher than the reported ranges of failures found in 
previous studies of cefotetan prophylaxis in colorectal surgery. 
Indeed, as the authors noted, in nine previous clinical trials of 
cefotetan prophylaxis in colorectal surgery the reported rates 
of surgical-site infections ranged from 9.4% to 28.0%, with 
a mean of 17.1%.78–86 This discrepancy can be explained at 
least in part by the inclusion of unexplained antibiotic use 
and anastomotic leakage, in addition to surgical site infections, 
in the failures of prophylaxis (7.5% and 4.2%, respectively). 
As for the high rate of superficial-site infection observed 
in the study by Itani and colleagues (22.4% in cefotetan 
group and 13.1% in ertapenem group), it should be noted 
that 28.9% of the patients evaluated had a body mass index 
(BMI) ± 30 kg/m2, which is much higher of the rates of obese 
patients usually included in other studies.82,83,86 Furthermore, 
in a post-hoc analysis performed using the data from the 
study by Itani and colleagues, the incidence of SSIs, and 
specifically of superficial incisional SSIs, was found to be 
higher in patients with a BMI ± 30 kg/m2 regardless of the 
prophylactic antibiotic (ertapenem or cefotetan) given.87 
Indeed, failure of antibiotic surgical prophylaxis in obese 
patients may be related both to technical factors, such as an 
inadequate obliteration of “dead spaces,” and to low drug 
levels in serum and tissues, especially at the end of an opera-
tion and during surgery.88 The possible occurrence of other 
surgical-related factors that could have contributed to the 
high rates of SSIs, such as failure to maintain normother-
mia, and uncontrolled hyperglycemia in the perioperative 
period,89 have not been analyzed in the study by Itani and 
colleagues. Finally, the high rates of resistance to cefotetan 
of microorganisms isolated in the failures of prophylaxis, 
seen in the post-hoc study by Goldstein and colleagues76 
(62.6% and 50.7% for aerobes and anaerobes, respectively), 
could have been a direct consequence of the repeated use of 
cefotetan as surgical prophylaxis in the centers participating 
in the study.
From the prophylactic, economic, and bacteriological 
points of view, ertapenem was found to be more effec-
tive than cefotetan in elective, open, colorectal surgery 
prophylaxis. On the basis of these results, ertapenem has 
been approved by the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMEA) in the 
US and Europe, respectively, for the prophylaxis of SSI 
following elective colorectal surgery in adults. It is reason-
able to wonder whether ertapenem should be considered the 
preferred antimicrobial agent for prophylaxis in colorectal 
surgery. However, three major considerations should be made 
on this subject prior to translation of this study’s conclusions 
in extensive clinical practice. First, several antibiotic regimens 
have been found not inferior to cefotetan in colorectal Therapeutics and Clinical Risk Management 2009:5 836
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surgery prophylaxis,43 and, so far, we do not have data that 
directly compare ertapenem with these antimicrobial agents. 
In comparing the relative efficacy of different antimicrobial 
agents in colorectal surgery prophylaxis, considerable 
discrepancies have been shown to exist between the direct 
and the indirect comparisons.90 Therefore we must be very 
cautious in extrapolating the relative prophylactic efficacy 
of different antimicrobial regimens by comparing the results 
of this trial with studies of other antimicrobial agents.91 The 
second important consideration is whether the extensive use 
of carbapenem predisposes patients and the community to 
the emergence of resistant microorganisms. Carbapenem 
resistance is a serious problem because imipenem and 
meropenem are the last resort against serious infections 
caused by multiresistant aerobic Gram-negative bacteria 
that produce extended spectrum beta-lactamases. Whether 
it is right to fear ertapenem as a major inducer of resistance 
is, however, less certain. Most carbapenem resistance is in 
nonfermenters, such as Pseudomonas spp and Acinetobacter 
spp, and these microorganisms are outside the spectrum 
of ertapenem. Furthermore, it has been found that bowel 
colonization with carbapenem-resistant Gram-negative bacilli 
is rarely observed following ertapenem treatment of intra-
abdominal infections,92 and it is difficult to find carbapenem 
resistance in Enterobacteriaceae, as demonstrated by its rarity 
many years after the launch of imipenem.64 It is certainly true 
that a single-dose antimicrobial prophylaxis is less likely to 
induce the emergence of drug-resistant microorganisms than 
is repeated administration. However, it should be noted that 
surgeons often prolong the duration of antimicrobial prophy-
laxis into the postoperative period,41 and the common experi-
ence shows that widespread use of any antimicrobial agent is 
followed, sooner or later, by the emergence of antimicrobial 
resistance to that antibiotic. The third important consideration 
that should be made prior to the translation of the study by 
Itani and colleagues into extensive clinical practice refers to 
the ertapenem effects on the intestinal gut flora. Indeed, the 
higher incidence of C. difficile infection in the ertapenem-
treated patients, even though not statistically significant, is a 
deep concern. C. difficile associated disease (CDAD) has been 
recognized as a nosocomial problem for more than 30 years,93 
especially in surgical and critical ill patients, but the epide-
miology of the disease is changing. The prevalence and the 
severity of CDAD continue to increase despite numerous 
discoveries concerning its epidemiology and the pathogenic-
ity of C. difficile.94,95 This increasing trend is associated with 
the emergence and spread of an epidemic strain referred to as 
NAP1/BI (North American pulsed-field type 1, ribotype 027, 
restriction endonuclease analysis type BI, toxinotype III).96,97 
As a result, the average hospital cost of CDAD patients is 
estimated to be 54% more that non-CDAD patients in the 
US,98 and length of hospital stay of CDAD patients also 
increases, ranging from an average of  3.6 days for the total 
patient population to 16 days for surgical inpatients.99 Several 
years ago we showed that C. difficile colonization can be 
induced also by single-dose antibiotic prophylaxis in surgery, 
suggesting that, when a comparable efficacy in preventing 
postoperative infections is proven for different antimicrobial 
agents, the rate of C. difficile colonization and disease should 
be taken into account in the choice of the most suitable agent 
for surgical prophylaxis.38 In our opinion these suggestions 
are even more important today on the basis of the increasing 
prevalence and severity of C.difficile infection.
Conclusions
The clinical superiority of ertapenem 1 g over cefotetan 
2 g for the prevention of SSIs following elective colorectal 
surgery was clearly demonstrated in a well designed and 
well controlled study. Given that single-dose cefotetan is so 
broadly used as a parenteral prophylactic agent in colorectal 
operations, should single-dose ertapenem be considered 
as the “gold standard” prophylactic regimen for elective 
colorectal surgery on the basis of this study? In other words, is 
ertapenem better that commonly used prophylactic regimens 
other than cefotetan for the prevention of SSI following 
colorectal operations? And, if so, does prophylaxis outweigh 
the risk of aggravate antimicrobial resistance and intestinal 
side effects of antimicrobial prophylaxis including C. difficile 
infection? These important questions will be answered by 
further comparative studies of ertapenem prophylaxis versus 
other widely used prophylactic regimens for colorectal 
surgery in patients submitted to MBP versus no preparation, 
as well as further research on adverse events of antibiotic 
prophylaxis, including the emergence of resistance and 
C. difficile colonization and infection.
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